Time Is On Eisai’s Side As More Long-Term Data Emerge For Leqembi

Dual Action Stands Out From Lilly’s Kisunla

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Leqembi for early Alzheimer’s disease now has an anti-amyloid competitor in the US with limited-term dosing, but new data at AAIC support chronic dosing of Eisai’s Biogen-partnered drug.

Caregiver cheers up senior lady patient touching hand while sits in armchairs in light room
Maintenance and subcutaneous dosing could reduce the burden of chronic Leqembi treatment • Source: Shutterstock

New long-term data on Eisai Co., Ltd./Biogen, Inc.’s early Alzheimer’s disease medicine Leqembi (lecanemab) presented at the Alzheimer’s Association International Conference (AAIC) indicate that chronic treatment has a better effect than short-term treatment, possibly negating what was thought to be a potential advantage for Eli Lilly and Company’s competing anti-amyloid antibody Kisunla (donanemab).

Key Takeaways

  • Eisai and Biogen have a first-to-market advantage in early Alzheimer’s disease with Leqembi, but a second anti-amyloid antibody has reached the market from Lilly with potential dosing advantages.

Leqembi has been on the market in the US since receiving accelerated approval in January 2023, giving it a year...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

 
• By Xu Hu

Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Sponsored By:

Nancy Tests SPARC-931-part

The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D

Scrip-R&D-Premium: ‘Article’ article that includes different Composer content

 
• By Nabil, Olga Zviezdicheva, Reed Miller, Mary Jo Laffler, Ian Schofield, João Andrés-Ruíz de la Fontaine-LeBlanc, Chloë Anastasía-Stojanović del Castillo-Ribeirão, and Nabil

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.